Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (220 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellto determinepriorphase iiiron
  Phrases that lowered it: kneestudy tohiphistorysuspected
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 6.2% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 33 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 10.2% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 230490 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 67.7% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: double (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 113 (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 26490 (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery NCT02189889 · started 2013 · scored riskier than 81% of active trials terminated
• Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency NCT03817957 · started 2018 · scored riskier than 35% of active trials completed
• HiFIT Study : Hip Fracture: Iron and Tranexamic Acid NCT02972294 · started 2017 · scored riskier than 73% of active trials terminated
• Preoperative Intravenous Iron to Treat Anaemia in Major Surgery NCT01692418 · started 2014 · scored riskier than 53% of active trials completed
• Efficacy of Preoperative Intravenous Iron in Anaemic Colorectal Cancer Surgical Patients NCT03565354 · started 2018 · scored riskier than 51% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.